A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...

The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 ...

A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.

The new pill, developed by Vertex Pharmaceuticals, is intended for short-term pain relief following surgery or injury ... but ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...

Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...

Chemotherapy has been known to cause damage to peripheral nerves, and sometimes the pain is chronic and severe enough that chemotherapy doses are reduced or discontinued. But prior research has not ...

Cannabidiol (CBD) holds promise as a treatment for many health concerns, including inflammation. For all the known benefits CBD offers, it’s unclear how well it can relieve nerve pain.

Traditional pain relief medication often relies on opioids by interacting with the body’s opioid receptors. Journavx works by targeting a specific pain-signaling pathway in the body. It affects ...